Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Zhongshan Kangfang Biological Medicine Co., LTD
Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026
May 20, 2026
Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
May 19, 2026
Akeso Reports Full-Year 2025 Financial Results
May 19, 2026
Akeso Advances “IO 2.0 + ADC 2.0” Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
May 18, 2026
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
May 16, 2026
Ivonescimab Included in FirstWord Pharma’s “The Drugs That Will Shape 2026”
January 29, 2026
Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis
January 19, 2026
Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer
January 14, 2026
Ivonescimab’s Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study
January 6, 2026
Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab
December 13, 2025
1
2
Next Page
→